Ironwood Pharmaceuticals (IRWD) Scheduled to Post Quarterly Earnings on Thursday

Ironwood Pharmaceuticals (NASDAQ:IRWD) will announce its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.08 per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

Ironwood Pharmaceuticals Stock Down 0.7 %

IRWD traded down $0.03 during trading on Tuesday, hitting $4.16. The company’s stock had a trading volume of 124,708 shares, compared to its average volume of 2,951,896. The business’s 50 day simple moving average is $4.34 and its 200-day simple moving average is $5.67. The firm has a market cap of $664.52 million, a PE ratio of 104.75 and a beta of 0.47. Ironwood Pharmaceuticals has a one year low of $3.79 and a one year high of $15.70.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, insider Minardo John sold 9,910 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, August 12th. The shares were sold at an average price of $4.27, for a total value of $42,315.70. Following the sale, the insider now directly owns 284,661 shares in the company, valued at approximately $1,215,502.47. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 12.90% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms recently weighed in on IRWD. Leerink Partnrs upgraded Ironwood Pharmaceuticals to a “hold” rating in a research report on Monday, September 9th. Leerink Partners started coverage on shares of Ironwood Pharmaceuticals in a report on Monday, September 9th. They issued a “market perform” rating and a $5.00 target price for the company. Capital One Financial downgraded shares of Ironwood Pharmaceuticals from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $12.00 to $4.00 in a report on Thursday, August 8th. Wells Fargo & Company reduced their price objective on shares of Ironwood Pharmaceuticals from $14.00 to $12.00 and set an “overweight” rating for the company in a research note on Friday, August 9th. Finally, Craig Hallum lowered their target price on shares of Ironwood Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, August 9th. Three research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $12.17.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.